ADARx Pharmaceuticals Files for IPO

Dow Jones

7小時前

ADARx Pharmaceuticals filed for an initial public offering.

The late-stage biotechnology company did not say how many shares it would sell or at what price, according to a Friday filing with the Securities and Exchange Commission.

It applied to list shares on the Nasdaq Global Market under the symbol ADRX.

ADARx focuses on siRNA therapeutics and has five programs in its pipeline addressing several indications, including obesity, Alzheimer's disease, and strokes, according to the filing.

The company said it would use proceeds from the IPO to advance the development of its programs and conduct additional research and development efforts.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2665354089"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2665354089\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2665354089?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-05 06:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2665354089","market":"fut","top_or_hot":-1,"title":"ADARx Pharmaceuticals Files for IPO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  ADARx Pharmaceuticals filed for an initial public offering. \n</p>\n<p>\n  The late-stage biotechnology company did not say how many shares it would sell or at what price, according to a Friday filing with the Securities and Exchange Commission. \n</p>\n<p>\n  It applied to list shares on the Nasdaq Global Market under the symbol ADRX. \n</p>\n<p>\n  ADARx focuses on siRNA therapeutics and has five programs in its pipeline addressing several indications, including obesity, Alzheimer's disease, and strokes, according to the filing. \n</p>\n<p>\n  The company said it would use proceeds from the IPO to advance the development of its programs and conduct additional research and development efforts. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADARx Pharmaceuticals Files for IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADARx Pharmaceuticals Files for IPO\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-09-05 06:15</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  ADARx Pharmaceuticals filed for an initial public offering. \n</p>\n<p>\n  The late-stage biotechnology company did not say how many shares it would sell or at what price, according to a Friday filing with the Securities and Exchange Commission. \n</p>\n<p>\n  It applied to list shares on the Nasdaq Global Market under the symbol ADRX. \n</p>\n<p>\n  ADARx focuses on siRNA therapeutics and has five programs in its pipeline addressing several indications, including obesity, Alzheimer's disease, and strokes, according to the filing. \n</p>\n<p>\n  The company said it would use proceeds from the IPO to advance the development of its programs and conduct additional research and development efforts. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FRHC","symbol_name":"Euronext CAC Health Care","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2665354089","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2665354089","pubTimestamp":1788560100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ADARx Pharmaceuticals filed for an initial public offering.The late-stage biotechnology company did not say how many shares it would sell or at what price, according to a Friday filing with the Securities and Exchange Commission.It applied to list shares on the Nasdaq Global Market under the symbol ADRX.ADARx focuses on siRNA therapeutics and has five programs in its pipeline addressing several indications, including obesity, Alzheimer's disease, and strokes, according to the filing.The company said it would use proceeds from the IPO to advance the development of its programs and conduct additional research and development efforts.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FRHC":"Euronext CAC Health Care","IPOS":"Renaissance International IPO ETF","KCE":"SPDR KBW Capital Markets ETF","BK4127":"投资银行业与经纪业","REDS":"RPM Republican Senate ETF"},"translate_title":"ADARx Pharmaceuticals申请IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FRHC":1.5,"KCE":1.5,"IPOS":1.5,"REDS":1.5},"content_text":"ADARx Pharmaceuticals filed for an initial public offering. \n\n\n  The late-stage biotechnology company did not say how many shares it would sell or at what price, according to a Friday filing with the Securities and Exchange Commission. \n\n\n  It applied to list shares on the Nasdaq Global Market under the symbol ADRX. \n\n\n  ADARx focuses on siRNA therapeutics and has five programs in its pipeline addressing several indications, including obesity, Alzheimer's disease, and strokes, according to the filing. \n\n\n  The company said it would use proceeds from the IPO to advance the development of its programs and conduct additional research and development efforts.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}